See more news releases in: Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Supplementary Medicine, Earnings Forecasts & Projections, Personnel Announcements
China-Biotics, Inc. Begins Trial Production at New Facility, Affirms 2010 Revenue Guidance
The Company added eight new bulk additive customers in September and
October, bringing its total number of bulk additive customers to 24. The
newly signed customers are mainly engaged in manufacture of dairy, nutritional
supplement, and animal feed products. The trial production of Phase I has
recently begun at its new state-of-the-art production facility in Qing Pu
Industrial Park in
"We are delighted to begin trial production at our new facility and start
the second phase of our capacity expansion, which we expect to complete by the
end of the year," said Mr.
The Company has strengthened it senior management team to support
operations at the new facility with the addition of Mr. Bin Li, vice general
manager of manufacturing and Dr.
About China-Biotics, Inc.
China-Biotics, Inc., a leading manufacturer of biotechnology products and
supplements, engages in the research, development, marketing and distribution
of probiotics dietary supplements. Through its wholly owned subsidiary,
Shanghai Shining Biotechnology Co., Ltd., the Company has operations in
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact:
Eva Yan, CFO
Email: evayan@chn-biotics.com
Web: htyp://www.chn-biotics.com
CCG Investor Relations
Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
SOURCE China-Biotics, Inc.
Back to top
RELATED LINKS
http://www.chn-biotics.com
http://www.ccgirasia.com
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
PR Newswire Membership
Fill out a PR Newswire membership form or contact us at (888) 776-0942.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
Featured Video
More in These Categories
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Free Investing Newsletter from Investor Uprising!
Learn to navigate the world's financial system and profit from leading companies.
Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All The Glitters: The Ultimate Gold Report".
